doi: 10.1186/s12891-022-05396-5 Summary Keywords type 2 diabetes, osteoporosis, GLP-1 receptor agonists, electronic medical records, cohort study, bone metabolism, fracture risk Citation Chen M, Lyu Y, Zhao J, Han X, Huang T, Yang T and Zhou Y (2025) Use of GLP-1 receptor agonist and risk of osteoporosis among patients with type 2 diabetes: a real-world study
This molecule is our most potent internal antioxidant and is present in almost every cell of the body with high concentrations in the liver
Anti-inflammatory Action & Potential DHT Blocking: Dihydrotestosterone (DHT) is the hormone responsible for androgenetic alopecia (pattern baldness)
Fracture Risk Data from GLP1 Trials Several cardiovascular outcomes trials (CVOTs) have collected fracture data as secondary outcomes: Trials involving semaglutide and dulaglutide generally report fracture rates similar to placebo A few studies suggest a potential increase in non-vertebral fractures, though findings are inconsistent and often not statistically significant One important confounder is weight loss, which itself can lead to bone loss
For many patients, that means fewer energy crashes, better consistency with eating habits, and a more manageable path toward steady weight loss
